Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials
Author:
Publisher
Maney Publishing
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology
Link
http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883
Reference28 articles.
1. Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial
2. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
3. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
4. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
5. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gastric cancer presenting with ramucirumab-related gastrocolic fistula successfully managed by colonic stenting: a case report;Clinical Endoscopy;2023-11-30
2. Delayed esophageal anastomotic complication and ramucirumab therapy: A case report;Thoracic Cancer;2023-09-04
3. Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System;Journal of Pharmacy & Pharmaceutical Sciences;2023-02-15
4. The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs;Gastroenterology Research and Practice;2021-02-22
5. Ramucirumab-Induced Hepatocellular Carcinoma Rupture and Gastrointestinal Perforation;American Journal of Case Reports;2021-02-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3